AstraZeneca Plc explored a potential acquisition of Bristol-Myers Squibb Co. in a deal estimated at $400 billion that would have ranked as the largest in pharmaceutical history, according to people familiar with the matter. AstraZeneca shares fell as much as 7 percent Monday after the reports became public.
Multiple analysts said the strategic rationale was unclear, describing the potential merger as a surprising departure from AstraZeneca's stated priorities. Investors appeared to prefer the company's existing trajectory over a deal of this scale.
A $400 billion acquisition would require substantial financing and likely alter AstraZeneca's capital structure, significantly increasing its debt load. Large pharmaceutical mergers of this size carry integration risks including combining corporate cultures, eliminating redundant operations and clearing regulatory hurdles across multiple jurisdictions.
Proponents of large pharma mergers typically cite expanded market share, pipeline diversification and enhanced research and development capacity. Those arguments did not appear to move investors, whose swift selloff suggests the talks did not progress beyond early exploratory stages.
The 7 percent decline represents a direct market verdict on the deal's perceived value. Analysts said any future large-scale acquisition by AstraZeneca would need a more compelling strategic case to win shareholder support.
